Mr Lachlan Monfries, Chair
Ms Stephanie Morris, Director
GAICD, MBA, BBus, DipBioMedSci
Stephanie is a life-sciences professional with enthusiasm for invention, technology transfer and commercialisation. She currently heads the translational activities for academic discovery and innovation for the Faculty of Medicine at Imperial College London. She has depth of expertise having worked within start-up companies, SMEs and large multinational pharmaceutical organisations at operational and governance levels. She has a unique breadth of experience across the full care continuum, including academia, R&D, clinical development, commercialisation, as well as working with patients in both acute and chronic settings in the community.
Stephanie brings a dynamic and global perspective to research commercialisation. She holds tertiary qualifications in both biomedical science and in business, has a Master’s in Business Administration (MBA) and is a graduate of the Australian Institute of Company Directors (AICD).
Ms Kayi Li, Director
CA, GAICD, MBA, BComm
Kayi is currently the Financial Controller and Investor Relations manager with Codan Limited. Working for a diverse multinational company has allowed Kayi to accumulate a wealth of accounting and management experience across different industries both domestically and internationally. She holds tertiary qualifications in Commerce from the University of South Australia, a member of Chartered Accountants of Australia and New Zealand, has a Master’s in Business Administration and is a graduate of the Australian Institute of Company Directors.
Mr Greg Savage, Director
Greg has been a manufacturing plant manager in Melbourne, Sydney and Brisbane over a 15 year period. The Sydney plant is one of the largest glass plants in the world with four furnaces, ten machine lines and 460 employees.
Managing more than 450 employees across two sites at the Spotswood Glass Plant and Box Hill Engineering facility, Greg led a major restructuring and business turn around in safety, quality, production efficiency and industrial relations relationships.
Ms Jo Close, Deputy Chair
BBiotech (Hons) GAICD GLF10
Jo is a scientist with an accomplished career in research strategy and management. She has managed major Centres, Institutes and programs within all three leading South Australian universities and undertaken formative roles within the local bioscience industry and investment sector. For five years, Jo ran a successful consulting business, primarily facilitating local research organisations to develop strategy and plan major, collaborative research projects.
Jo has also established and led a range of industry development programs for local and international markets. Her contributions expand to the fundraising and community development areas, where Jo has driven a range of high-impact initiatives. Jo has completed the Company Director’s Course and is a fellow of the Governor’s Leadership Foundation.
Mr Clinton Jury, Director
GAICD, AdvDip Bus Mgt, Dip Mktg
Chair Risk, Governance & HR Committee
Clinton joined the Board in August 2018 and we welcomed his extensive not-for-profit and fundraising experience. Clinton is currently the State Manager SA/NT for the Australian Institute of Company Directors (AICD) and has extensive experience in leading organisations across adult education, strategic project management, marketing and commercial operations as well as major fundraising programs and member and volunteer management. Holding senior Director and Management roles in the NFP sector for more than 25 years Clinton has worked across many organisations including the Women’s and Children’s Hospital Foundation, Australian Red Cross, Royal Flying Doctor Service & CanTeen. Clinton is passionate about the creation of vibrant communities which bring people together and is excited to work alongside the CF community in search of a cure.
Ms Megan Webster Bradman, Director
BA, LLB(Hons), MPA
Megan is passionate about supporting the local community, having held a range of Board roles and volunteer positions in the community over many years. She has served on the Board of the Cure4 Cystic Fibrosis (Cure4CF) Foundation since 2014.
As a senior public sector executive, working across Federal, State and local governments, Megan brings a wealth of expertise in government relations, and higher education and health policy. Megan is a strategist and leader of change, successfully delivering transformational change projects for State government, local government, and the South Australian Courts.
Megan currently serves on the Executive Board of the Australian Medical Association (AMA) South Australia. She was a former Chair and Deputy Chair of the Regional Development Association (RDA) Adelaide, Director of Unibooks, and Council member of the State Records Council.
Megan graduated from the University of Adelaide with an Honours Degree of the Bachelor of Laws and a Bachelor of Arts. She also holds a Master of Public Administration from Flinders University. She has four children, all of whom have been enthusiastic supporters of Cure4CF in various capacities over the last 6 years.
Mr Greg Oke, Director
BAppSc (Met), MBA, MCIPS
Greg is currently managing his own business and has significant senior management experience in the mining, automotive and manufacturing industries.
Ms Jenna Dikih, Director
LLB (Hons), BCom, GDipLegalPrac, GradDipCA
Jenna is a legal practitioner and business professional with experience in private practice and not for profit sectors. Jenna currently works at AnglicareSA as one of their Legal Counsel, assisting in identifying risks to the organisation and helping achieve strategic and operational goals. She also brings significant experience from her previous role, specialising in business advisory, taxation and structuring issues.
Jenna holds a Bachelor of Laws (Honours) and is a Legal Practitioner admitted to the Supreme Court of South Australia. She is also a Chartered Accountant, and holds a Bachelor of Commerce.
Jenna is passionate about assisting the community. She joined the board in 2020 and is excited about working with Cure4CF towards the delivery of its vision.